Evolved metabolites already treat many cancers. We are discovering the next generation.
Many of the pathways that drive cancer growth are targeted by natural products – such as topoisomerase inhibitors, tubulin inhibitors, DNA damaging agents, and more. These molecules evolved to inhibit cell growth and are valuable anti-cancer agents. New technologies have revealed the next-generation of targeted therapies, particularly as novel payloads for antibody drug conjugates, for cancer treatments.
David Goeddel, PhD, Chairman
Managing Partner, The Column Group
Maureen Hillenmeyer, PhD
CEO & Co-Founder, Hexagon Bio
Juan Jaen, PhD
President, Arcus Biosciences
Jakob Loven, PhD
Managing Partner, Nextech Invest
Millie Ray, PhD
Partner, The Column Group
Alex Kolicich
Founding Partner, 8VC
Yujiro S. Hata
President and CEO, IDEAYA Biosciences
John Josey, PhD
Venture Partner, The Column Group
Steven McKnight, PhD
Distinguished Chair in Basic Biomedical Research, UT Southwestern Medical Center
Marnix Medema, PhD
Professor of Bioinformatics at Wageningen University & Research
Frank C. Schroeder, PhD
Professor, Boyce Thompson Institute
Professor, Department of Chemistry and Chemical Biology, Cornell University
Anthony Tolcher, MD
NEXT Oncology, CEO, Founder and Director of Clinical Research
Investors
We have assembled leading technology- and life science-focused investors who believe in and support our ambition to become the world-leading company in developing human therapeutics from metagenomes.